Adalimumab, one of anti-tumor necrosis factor (anti-TNF) drugs, is an approved biologic therapy for uveitis, of which the efficacy and safety were shown in phase 3 randomized-controlled trials involving patients with VKH disease15,16. Here, TNF is linked to uveitis.